---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-017454"
form_type: "8-K"
ticker: "STOK"
cik: "0001623526"
company_name: "Stoke Therapeutics, Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T22:09:49.639708+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Stoke Therapeutics Q1 2023 net loss $0.53/sh; cash $254.2M; mid-2023 STK-001 data expected

## Summary
- Net loss per share $0.53, revenue $5.2M from collaboration (up from $3.0M YoY).
- Cash, equivalents and securities $254.2M, expected to fund operations to end of 2025.
- On track to report Phase 1/2a STK-001 data mid-2023: safety & seizure frequency for up to 16 patients on 45mg.
- UK MHRA authorized CTA for STK-002 Phase 1/2 study in ADOA; start expected early 2024.
- Company plans to initiate a Phase 3 program in 2024, pending additional Phase 1/2a data.

## SEC filing metadata
- accession: 0000950170-23-017454
- form_type: 8-K
- ticker: STOK
- cik: 0001623526
- company_name: Stoke Therapeutics, Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1623526/000095017023017454/0000950170-23-017454-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1623526/000095017023017454/stok-20230504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-017454
- JSON: https://secwatch.observer/filing/0000950170-23-017454.json
- Plain text: https://secwatch.observer/filing/0000950170-23-017454.txt

## Key facts
- Earnings Releases
  Stoke Therapeutics, Inc. reported three months ended March 31, 2023 results: net income -$22.5 million, EPS -$0.53.
  - Period: three months ended March 31, 2023
  - Net income: -$22.5 million
  - EPS: -$0.53
  - Result: reported results
  source text: Net loss for the three months ended March 31, 2023 was $22.5 million, or $0.53 per share, compared to $24.6 million, or $0.66 per share, for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1623526/000095017023017454/0000950170-23-017454-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.